Page last updated: 2024-08-24

simendan and Diabetes Mellitus, Type 2

simendan has been researched along with Diabetes Mellitus, Type 2 in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (66.67)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bugajski, J; Duszańska, A; Feusette, P; Gierlotka, M; Płonka, J	1
Finckenberg, P; Forsten, H; Kaheinen, P; Kytö, V; Leskinen, H; Levijoki, J; Louhelainen, M; Merasto, S; Mervaala, E; Tikkanen, I; Vahtola, E	1
Al-Shawaf, E; Ayed, A; Dehrab, N; Radomir, B; Tarazi, R; Vislocky, I	1

Trials

1 trial(s) available for simendan and Diabetes Mellitus, Type 2

Article	Year
Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery. Journal of cardiothoracic and vascular anesthesia, 2006, Volume: 20, Issue:3 Topics: Adult; Aged; Blood Pressure; Cardiac Output, Low; Cardiopulmonary Bypass; Coronary Artery Bypass; Diabetes Mellitus, Type 2; Elective Surgical Procedures; Female; Humans; Hydrazones; Male; Middle Aged; Milrinone; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Stroke Volume; Vascular Resistance	2006

Article

Year

Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery.

Journal of cardiothoracic and vascular anesthesia, 2006, Volume: 20, Issue:3

Topics: Adult; Aged; Blood Pressure; Cardiac Output, Low; Cardiopulmonary Bypass; Coronary Artery Bypass; Diabetes Mellitus, Type 2; Elective Surgical Procedures; Female; Humans; Hydrazones; Male; Middle Aged; Milrinone; Phosphodiesterase Inhibitors; Pyridazines; Simendan; Stroke Volume; Vascular Resistance

2006

Other Studies

2 other study(ies) available for simendan and Diabetes Mellitus, Type 2

Article	Year
Levosimendan – a valuable player in the treatment of a right-sided heart failure Wiadomosci lekarskie (Warsaw, Poland : 1960), 2019, Aug-31, Volume: 72, Issue:8 Topics: Aged; Cardiotonic Agents; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hydrazones; Male; Pyridazines; Simendan	2019
Oral levosimendan prevents postinfarct heart failure and cardiac remodeling in diabetic Goto-Kakizaki rats. Journal of hypertension, 2009, Volume: 27, Issue:10 Topics: Administration, Oral; Animals; Apoptosis; Blood Pressure; Cardiomegaly; Cardiotonic Agents; Cyclin-Dependent Kinase Inhibitor p16; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Models, Animal; Heart Failure; Homeodomain Proteins; Hydrazones; Male; Myocardial Infarction; Pyridazines; Rats; Rats, Mutant Strains; Rats, Wistar; RNA, Messenger; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; STAT1 Transcription Factor; Ventricular Remodeling	2009

Article

Year

Levosimendan – a valuable player in the treatment of a right-sided heart failure

Wiadomosci lekarskie (Warsaw, Poland : 1960), 2019, Aug-31, Volume: 72, Issue:8

Topics: Aged; Cardiotonic Agents; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hydrazones; Male; Pyridazines; Simendan

2019

Oral levosimendan prevents postinfarct heart failure and cardiac remodeling in diabetic Goto-Kakizaki rats.

Journal of hypertension, 2009, Volume: 27, Issue:10

Topics: Administration, Oral; Animals; Apoptosis; Blood Pressure; Cardiomegaly; Cardiotonic Agents; Cyclin-Dependent Kinase Inhibitor p16; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Models, Animal; Heart Failure; Homeodomain Proteins; Hydrazones; Male; Myocardial Infarction; Pyridazines; Rats; Rats, Mutant Strains; Rats, Wistar; RNA, Messenger; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Simendan; STAT1 Transcription Factor; Ventricular Remodeling

2009